Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Cereb Blood Flow Metab ; 41(11): 2870-2886, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34259069

RESUMO

Traumatic brain injury (TBI) is commonly followed by long-term cognitive deficits that severely impact the quality of life in survivors. Recent studies suggest that microglial/macrophage (Mi/MΦ) polarization could have multidimensional impacts on post-TBI neurological outcomes. Here, we report that repetitive intranasal delivery of interleukin-4 (IL-4) nanoparticles for 4 weeks after controlled cortical impact improved hippocampus-dependent spatial and non-spatial cognitive functions in adult C57BL6 mice, as assessed by a battery of neurobehavioral tests for up to 5 weeks after TBI. IL-4-elicited enhancement of cognitive functions was associated with improvements in the integrity of the hippocampus at the functional (e.g., long-term potentiation) and structural levels (CA3 neuronal loss, diffusion tensor imaging of white matter tracts, etc.). Mechanistically, IL-4 increased the expression of PPARγ and arginase-1 within Mi/MΦ, thereby driving microglia toward a global inflammation-resolving phenotype. Notably, IL-4 failed to shift microglial phenotype after TBI in Mi/MΦ-specific PPARγ knockout (mKO) mice, indicating an obligatory role for PPARγ in IL-4-induced Mi/MΦ polarization. Accordingly, post-TBI treatment with IL-4 failed to improve hippocampal integrity or cognitive functions in PPARγ mKO mice. These results demonstrate that administration of exogenous IL-4 nanoparticles stimulates PPARγ-dependent beneficial Mi/MΦ responses, and improves hippocampal function after TBI.


Assuntos
Lesões Encefálicas Traumáticas/psicologia , Disfunção Cognitiva/tratamento farmacológico , Interleucina-4/farmacologia , Microglia/patologia , PPAR gama/efeitos dos fármacos , Adjuvantes Imunológicos/administração & dosagem , Adjuvantes Imunológicos/farmacologia , Administração Intranasal , Animais , Lesões Encefálicas Traumáticas/complicações , Lesões Encefálicas Traumáticas/patologia , Região CA3 Hipocampal/diagnóstico por imagem , Região CA3 Hipocampal/metabolismo , Cognição/efeitos dos fármacos , Disfunção Cognitiva/diagnóstico , Disfunção Cognitiva/etiologia , Imagem de Tensor de Difusão/métodos , Modelos Animais de Doenças , Hipocampo/efeitos dos fármacos , Hipocampo/fisiologia , Inflamação/complicações , Inflamação/metabolismo , Interleucina-4/administração & dosagem , Potenciação de Longa Duração/efeitos dos fármacos , Potenciação de Longa Duração/fisiologia , Ativação de Macrófagos/efeitos dos fármacos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Microglia/efeitos dos fármacos , Microglia/metabolismo , Nanopartículas/administração & dosagem , PPAR gama/metabolismo , Fenótipo , Qualidade de Vida , Substância Branca/diagnóstico por imagem , Substância Branca/metabolismo
2.
J Cereb Blood Flow Metab ; 41(3): 511-529, 2021 03.
Artigo em Inglês | MEDLINE | ID: mdl-32757740

RESUMO

Long-term neurological recovery after severe traumatic brain injury (TBI) is strongly linked to the repair and functional restoration of injured white matter. Emerging evidence suggests that the anti-inflammatory cytokine interleukin-4 (IL-4) plays an important role in promoting white matter integrity after cerebral ischemic injury. Here, we report that delayed intranasal delivery of nanoparticle-packed IL-4 boosted sensorimotor neurological recovery in a murine model of controlled cortical impact, as assessed by a battery of neurobehavioral tests for up to five weeks. Post-injury IL-4 treatment failed to reduce macroscopic brain lesions after TBI, but preserved the structural and functional integrity of white matter, at least in part through oligodendrogenesis. IL-4 directly facilitated the differentiation of oligodendrocyte progenitor cells (OPCs) into mature myelin-producing oligodendrocytes in primary cultures, an effect that was attenuated by selective PPARγ inhibition. IL-4 treatment after TBI in vivo also failed to stimulate oligodendrogenesis or improve white matter integrity in OPC-specific PPARγ conditional knockout (cKO) mice. Accordingly, IL-4-afforded improvements in sensorimotor neurological recovery after TBI were markedly impaired in the PPARγ cKO mice compared to wildtype controls. These results support IL-4 as a potential novel neurorestorative therapy to improve white matter functionality and mitigate the long-term neurological consequences of TBI.


Assuntos
Lesões Encefálicas Traumáticas/tratamento farmacológico , Interleucina-4/uso terapêutico , Oligodendroglia/metabolismo , PPAR gama/metabolismo , Substância Branca/patologia , Administração Intranasal , Animais , Comportamento Animal/efeitos dos fármacos , Diferenciação Celular/efeitos dos fármacos , Células Cultivadas , Interleucina-4/química , Interleucina-4/farmacologia , Lipossomos/química , Masculino , Camundongos , Camundongos Transgênicos , Bainha de Mielina/metabolismo , Oligodendroglia/citologia , PPAR gama/deficiência , PPAR gama/genética , Recuperação de Função Fisiológica
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA